[go: up one dir, main page]

WO2012010942A3 - Novel pharmaceutical composition(s) of hiv protease inhibitor(s) - Google Patents

Novel pharmaceutical composition(s) of hiv protease inhibitor(s) Download PDF

Info

Publication number
WO2012010942A3
WO2012010942A3 PCT/IB2011/001656 IB2011001656W WO2012010942A3 WO 2012010942 A3 WO2012010942 A3 WO 2012010942A3 IB 2011001656 W IB2011001656 W IB 2011001656W WO 2012010942 A3 WO2012010942 A3 WO 2012010942A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
hiv protease
protease inhibitor
novel pharmaceutical
encapsulated
Prior art date
Application number
PCT/IB2011/001656
Other languages
French (fr)
Other versions
WO2012010942A2 (en
Inventor
Ashish Ashokrao Deshmukh
Pravin Meghrajji Bhutada
Sajeev Chandran
Shirishkumar Kulkarni
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2012010942A2 publication Critical patent/WO2012010942A2/en
Publication of WO2012010942A3 publication Critical patent/WO2012010942A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an alcohol free, soluble, stable, taste masked pharmaceutical composition(s) for the administration of HIV protease inhibitors and pharmaceutically acceptable salts thereof. These compositions can optionally be encapsulated in hard or soft gelatin capsules.
PCT/IB2011/001656 2010-07-22 2011-07-18 Novel pharmaceutical composition(s) of hiv protease inhibitor(s) WO2012010942A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN805/KOL/2010 2010-07-22
IN805KO2010 2010-07-22

Publications (2)

Publication Number Publication Date
WO2012010942A2 WO2012010942A2 (en) 2012-01-26
WO2012010942A3 true WO2012010942A3 (en) 2012-05-24

Family

ID=44653361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/001656 WO2012010942A2 (en) 2010-07-22 2011-07-18 Novel pharmaceutical composition(s) of hiv protease inhibitor(s)

Country Status (1)

Country Link
WO (1) WO2012010942A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006043A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US5948436A (en) * 1993-09-13 1999-09-07 Abbott Laboratories Pharmaceutical composition
WO2002036110A2 (en) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
US6521651B1 (en) * 1996-11-21 2003-02-18 Abbott Laboratories Pharmaceutical composition
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
BR0202252A (en) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Stable soluble pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical compositions for administration of hiv protease inhibitors
BR0302523A (en) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Stable pharmaceutical composition for administration of hiv protease inhibitors and process for obtaining concentrated pharmaceutical composition for administration of hiv protease inhibitors
JP4468115B2 (en) 2004-08-30 2010-05-26 株式会社ルネサステクノロジ Semiconductor device

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948436A (en) * 1993-09-13 1999-09-07 Abbott Laboratories Pharmaceutical composition
US6521651B1 (en) * 1996-11-21 2003-02-18 Abbott Laboratories Pharmaceutical composition
WO1999006043A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
WO2002036110A2 (en) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
WO2005018530A2 (en) * 2003-08-25 2005-03-03 Foamix Ltd. Penetrating pharmaceutical foam

Also Published As

Publication number Publication date
WO2012010942A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
MX388963B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IN2014MN01706A (en)
WO2012021715A3 (en) Stable formulations of linaclotide
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012035480A3 (en) Pharmaceutical compositions of curcumin
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
UA110979C2 (en) Liquid pharmaceutical formulation comprising nitisinone
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
MY173873A (en) Oral dosage forms of bendamustine
EA200801614A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MONTELUKAST
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2012064304A3 (en) Combinations comprising montelukast
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse
WO2012010942A3 (en) Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2014013505A3 (en) Amorphous vildagliptin
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
MX2009006735A (en) Gelatin capsules comprising an acid.
WO2012033348A3 (en) Composition for the prevention or treatment of allergic diseases comprising 2-linoleoyl glycerol
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
WO2010108856A8 (en) Leukotriene b4 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11757931

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11757931

Country of ref document: EP

Kind code of ref document: A2